Tasquinimod failure sends Ipsen and Active Biotech shares tumbling
Active Biotech and Ipsen have dropped development of the immunotherapy candidate tasquinimod in prostate cancer after its "unambiguous" failure in a Phase III trial.
Active Biotech and Ipsen have dropped development of the immunotherapy candidate tasquinimod in prostate cancer after its "unambiguous" failure in a Phase III trial.